You are here

  • Home
  • Archive
  • Volume 65, Issue Suppl 1
  • PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom

Alerts

Article menu
Download PDFPDF
BSG 2016
PTH-084 Cost-Effectiveness of Vedolizumab Compared with Infliximab, Adalimumab, and Golimumab for Treatment of Moderately-to-Severely Active Ulcerative Colitis in The United Kingdom
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address